OptimizeRx (NASDAQ:OPRX) Receives “Buy” Rating from Lake Street Capital

Lake Street Capital reiterated their buy rating on shares of OptimizeRx (NASDAQ:OPRX) in a report issued on Tuesday,Benzinga reports. Lake Street Capital currently has a $11.00 target price on the stock.

A number of other equities research analysts have also recently commented on the stock. Barclays reduced their target price on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, November 14th. Roth Mkm reaffirmed a “buy” rating and set a $16.00 price objective (down previously from $20.00) on shares of OptimizeRx in a research note on Thursday, November 14th. Royal Bank of Canada decreased their target price on shares of OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. Stifel Nicolaus dropped their price target on OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Finally, JMP Securities reduced their price objective on OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 14th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.19.

OptimizeRx Stock Up 4.7 %

Shares of NASDAQ OPRX opened at $5.17 on Tuesday. The firm has a market cap of $95.24 million, a price-to-earnings ratio of -3.89 and a beta of 1.34. The company’s 50-day simple moving average is $5.25 and its 200-day simple moving average is $7.65. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx has a 52-week low of $3.78 and a 52-week high of $16.65.

Insiders Place Their Bets

In other news, CEO William J. Febbo bought 20,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $5.01 per share, with a total value of $100,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 601,253 shares in the company, valued at approximately $3,012,277.53. The trade was a 3.44 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On OptimizeRx

Large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its position in OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after purchasing an additional 2,414 shares in the last quarter. Quest Partners LLC raised its stake in shares of OptimizeRx by 15,965.6% during the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after buying an additional 9,739 shares during the last quarter. Connors Investor Services Inc. boosted its position in shares of OptimizeRx by 15.1% in the 2nd quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock worth $191,000 after buying an additional 2,500 shares in the last quarter. Barclays PLC grew its stake in OptimizeRx by 358.5% in the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after acquiring an additional 21,060 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new position in OptimizeRx during the 2nd quarter valued at about $282,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.